Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

NCT06107153 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

243

Enrollment

OTHER

Sponsor class

Conditions

Type2diabetes

Interventions

DRUG: Insulin Glargine 100 UNT/ML Pen Injector [Lantus]
DRUG: Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
DRUG: Pioglitazone 30mg

Sponsor

University of Basrah